May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
The Effect of Bevacizumab on Corneal Neovascularization in Rabbits
Author Affiliations & Notes
  • H. Hwang
    Department of Ophthalmology and Visual science, The Catholic University of Korea. Kangnam St. Mary Hospital, Seoul, Republic of Korea
  • E. Jeon
    Department of Ophthalmology and Visual science, The Catholic University of Korea. St. Paul Hospital, Seoul, Republic of Korea
  • S. Chung
    Department of Ophthalmology and Visual science, The Catholic University of Korea. St. Mary Hospital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  H. Hwang, None; E. Jeon, None; S. Chung, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1477. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      H. Hwang, E. Jeon, S. Chung; The Effect of Bevacizumab on Corneal Neovascularization in Rabbits . Invest. Ophthalmol. Vis. Sci. 2008;49(13):1477. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To determine the efficacy of topical bevacizumab in the treatment of corneal neovascularization.

Methods: : Corneal neovascularization was induced with a slik suture of the corneal stroma in 8 rabbits(16 eyes). One week after suturing, 4 rabbits were treated with topical bevacizumab 5 mg/ml (A group) and another 4 rabbits were treated with topical bevacizumab 10 mg/ml (B group) in the right eyes twice a day. The left eyes were used as the control. The area of corneal neovascularization was measured and evaluated histologically using light microscopy. The concentration of vascular endothelial growth factor(VEGF) in corneal tissue was measured.

Results: : Mean area of new vessels was 0.8260±0.037(1week) and 0.7363±0.039(2weeks) in control group. And mean area was 0.6242±0.049(1week), 0.4566±0.056(2weeks) in A group, 0.5808±0.052(1week), 0.3957±0.027(2weeks) in B group.The neovascularized area was smaller in A and B groups than control group (P<0.001). Mean concentration of VEGF was 1284.33±223.01 pg/ml in control group, 998.33±130.93 pg/ml in A group, and 942.00±32.86 pg/ml in B group.The histologic examination revealed fewer corneal vessels and the concentration of VEGF was also lower (P<0.01) in the treated group.

Conclusions: : Topical bevacizumab may be useful in treatment of the corneal neovascularization and a further study will be necessary.

Keywords: cornea: clinical science • vascular endothelial growth factor • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×